NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Serif Biomedicines

Serif Biomedicines

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://serifbiomedicines.com/

Last Round

Early Funding

Apr 21, 2026

Total Funding Raised

$50M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Serif Biomedicines is a biotechnology company pioneering Modified DNA as a new class of medicines, enabling programmable, scalable, durable, and redosable therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

Modified DNAgenetic medicinenon-viral gene therapyrare genetic diseasesimmune programmingLNP delivery systemredosable therapytherapeutic modalityprogrammable medicinedrug discovery platformgene therapy 2.0nucleic acid therapeuticsimmunology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Serif Biomedicines Comps

Public and private peers based on sector, stage, and business model.

Serif Biomedicines comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Serif Biomedicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 21, 2026

Serif Biomedicines Investors

Notable investors and investment history

Serif Biomedicines investors
InvestorRounds
Flagship PioneeringEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    $50M raised in early funding round.

Serif Biomedicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Serif Biomedicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Serif Biomedicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2021
Last FundingApr 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.